The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

The Agency for Healthcare Research and Quality (AHRQ) was created when Congress passed, and President Clinton signed, the Healthcare Research and Quality Act of 1999.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

From snake oil to cigarettes for asthma patients, the Pharmacy Museum is a trip through decades of healthcare evolution in California.

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different. The new administration wasted no time implementing ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

A Newsom 2028 presidential run may be in the works based on the California governor's recent moves, but his failures could haunt a future White House bid.

A roundup of the most newsworthy healthcare press releases from PR Newswire, including business strategies shaping the future ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...